Coagulopathy, Congenital Heart Disease
Conditions
Brief summary
When small children undergo heart surgery with the heart-lung machine, in the past, blood products to help the blood clot such as Fresh Frozen Plasma (FFP) was routinely used in children under 10kg. With blood clot monitoring technology, we feel that it might not be necessary to expose all children to FFP. We want to determine if those children who did not receive FFP bleed more or require more blood products as compared to those who did receive FFP while on the heart lung machine.
Detailed description
This will be a single center, retrospective study. Our cohort will include pediatric patients between 4 and 8 kilograms undergoing congenital cardiac surgery with cardiopulmonary bypass between January 2019 and January 2023. Patients will be divided into two groups: FFP given at onset of CPB and no FFP given intraoperatively. Patients requiring FFP for heparin resistance and anti-thrombin III deficiency will be excluded. Patient clinical, surgical, and bypass characteristics, transfusion, and bleeding outcomes will be collected using REDCAP and via chart review using Connect Care.
Interventions
None listed
Sponsors
University of Alberta
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
Yes
Inclusion criteria
* pediatric patients between 4 and 8 kilograms undergoing congenital cardiac surgery with cardiopulmonary bypass
Exclusion criteria
* Patients requiring FFP for heparin resistance and anti-thrombin III deficiency will be excluded
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Transfusion | 24 hours | Units of blood products transfused |
| Bleeding | 24 hours | Chest tube output |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Length of ventilation | 5 days | Time to extubation |
| Length of stay | 5 days | Time to ICU ready for discharge |
Countries
Canada
Outcome results
None listed